Why the study?
Does bivalirudin reduce bleeding without loss of anti-thrombotic efficacy compared to heparin-based strategies in patients with ACS or undergoing PCI?
Population
Patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)
Comparison
Bivalirudin (direct thrombin inhibitor) vs Unfractionated heparin or low-molecular-weight…
Design
Review
Authors
Loading...
Bivalirudin may reduce bleeding in ACS/PCI without ischemic loss; extends trial data but leaves open need for updated guidance.
Does bivalirudin reduce bleeding without loss of anti-thrombotic efficacy compared to heparin-based strategies in patients with ACS or undergoing PCI?
Bivalirudin is a safe, effective, and potentially cost-saving alternative to heparin plus GP IIb/IIIa inhibitors in ACS and PCI, primarily driven by a significant reduction in bleeding complications.
Lehman et al. (2006) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: